Business Daily cover image

Business Weekly

Business Daily

00:00

The New Treatment for Early Stage Alsimers - Biagins Ad Canmab

Altheimus is a degenerative and incurable disease. Nearly forty four million people live with it, out of which about six million are in the us. Average life expectancy is eight to ten years. The fda conditionally approving first new treatment for the disease in nearly two decades. Biagins ad canmab will be monthly infusion for patients with early stage alsimers.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app